Medical supply and device firm Covidien (NYSE:COV) reported second quarter results late in April 2012 and modest sales growth. It hopes that by spinning off a stodgier division to investors it will be able to boost its total growth trends going forward, and this could help it bridge its current valuation discount with a number of purer-play rivals.

Investopedia Broker Guides: Enhance your trading with the tools from today's top online brokers.

First Quarter Recap
Net sales advanced 5% and reached nearly $3 billion. Medical device (instruments, soft tissue repair products, airway and ventilation devices) sales increased 7% to $2 billion, or two thirds of the total top line. United States growth of 8% exceeded international growth, which grew 7%. Pharmaceutical sales (specialty pharmaceutical drugs and ingredients) were the next largest category and grew 5% to make up just over 17% of the top line. U.S. growth of 6% again exceeded international growth of 2%. The remaining segment is medical supplies (nursing, medical care products), which was flat and accounted for the remaining roughly 15% of total sales.

Lower product costs and restructuring charges helped send operating income up 7% to almost $1.3 billion. This represented a healthy operating margin of 21.3% of total sales. A drop in tax expenses further boosted net income to $991 million for growth of 12.4% from last year's first quarter. Earnings rose 15.3% to $2.04, due to share buybacks.

SEE: A Breakdown Of Stock Buybacks

Outlook and Valuation
Analysts project full year 2012 sales of nearly 3% and total sales of $11.9 billion. The consensus earnings projection currently stands at $4.30 per share and would represent annual growth above 31%. At the current share price of $56, the forward P/E is 12. This is slightly below Becton Dickinson's (NYSE:BDX) forward P/E of 12.5 and C.R. Bard's (NYSE:BCR) multiple of 14.

The Bottom Line
Since its spinoff from Tyco (NYSE:TYC) in 2007, Covidien has managed to boost sales 30% and profits at a similar level after posting a loss the year it was spun out. Since that time, its stock is up around 20% to lead the pack, along with Bard. It also beats the overall market return, which is roughly down 10%.

Despite these decent trends, management has chosen to shake things up and will be spinning off the pharmaceutical unit to investors in yet another spinoff. The announcement was made on Dec. 15, 2011 when pharma was estimated to log $2 billion in annual sales. It will be a top 10 player in the generic drug space and is also a large producer of bulk acetaminophen that is used in pain medication. It should free up Covidien to focus on growing its medical businesses and leave pharma to compete in the drug space along with larger rival Teva Pharmaceutical (Nasdaq:TEVA).

SEE: 5 Must-Have Metrics For Value Investors

Use the Investopedia Stock Simulator to trade the stocks mentioned in this stock analysis, risk free!

At the time of writing, Ryan C. Fuhrmann did not own shares in any of the companies mentioned in this article.

Related Articles
  1. Stock Analysis

    Analyzing Altria's Return on Equity (ROE) (MO)

    Learn about Altria Group's return on equity (ROE) and analyze net profit margin, asset turnover and financial leverage to determine what is causing its high ROE.
  2. Investing News

    Icahn's Bet on Cheniere Energy: Should You Follow?

    Investing legend Carl Icahn continues to lose money on Cheniere Energy, but he's increasing his stake. Should you follow his lead?
  3. Stock Analysis

    Analyzing Google's Return on Equity (ROE) (GOOGL)

    Learn about Alphabet's return on equity. How has its ROE changed over time, how does it compare to its peers and what factors are driving ROE for the company?
  4. Investing News

    Is Buffett's Bet on Oil Right for You? (XOM, PSX)

    Oil stocks are getting trounced, but Warren Buffett still likes one of them. Should you follow the leader?
  5. Investing News

    Chipotle Served with Criminal Probe

    Chipotle's beat muted expectations and got a clear bill from the CDC, but it now appears that an investigation into its E.coli breakout has expanded.
  6. Stock Analysis

    Analyzing Sprint Corp's Return on Equity (ROE) (S)

    Learn about Sprint's return on equity. Find out why its ROE is negative and how asset turnover and financial leverage impact ROE relative to Sprint's peers.
  7. Stock Analysis

    Why Alphabet is the Best of the 'FANGs' for 2016

    Alphabet just impressed the street, but is it the best FANG stock?
  8. Investing News

    A 2016 Outlook: What January 2009 Can Teach Us

    January 2009 and January 2016 were similar from an investment standpoint, but from a forward-looking perspective, they were very different.
  9. Mutual Funds & ETFs

    3 Vanguard Equity Fund Underperformers

    Discover three funds from Vanguard Group that consistently underperform their indexes. Learn how consistent most Vanguard low-fee funds are at matching their indexes.
  10. Investing News

    Alphabet Earnings Beat Expectations (GOOGL, AAPL)

    Alphabet's earnings crush analysts' expectations; now bigger than Apple?
RELATED FAQS
  1. How do dividends affect retained earnings?

    When a company issues a cash dividend to its shareholders, the retained earnings listed on the balance sheet are reduced ... Read Full Answer >>
  2. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  3. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  4. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>
  5. What types of capital are not considered share capital?

    The money a business uses to fund operations or growth is called capital, and there are a number of capital sources available. ... Read Full Answer >>
  6. What is the difference between issued share capital and subscribed share capital?

    The difference between subscribed share capital and issued share capital is the former relates to the amount of stock for ... Read Full Answer >>
COMPANIES IN THIS ARTICLE
Trading Center